INTRODUCTION AND OBJECTIVES:
This study is to investigate the status of therapeutic agents for dysuria and recurrence in Nonmuscle invasive bladder cancer (NMIBC) two groups between non-BCG therapy and BCG therapy.
METHODS: NMIBC 192 cases between June 2009 and February 2017 were participated. We divided into two groups, non-BCG group and BCG group, and compared the scores of CUETO risk and presence or absence of oral history therapeutic agents for dysuria such as, a-1 inhibitor, distigmine bromide, dutasteride and tadalafil. Anticholinergic agent and b-3 adrenoceptor agonist 3 were excluded in terms of therapeutic agents for dysuria. A case of presence agents for dysuria was defined as has being medicated before the primary recurrence.
RESULTS: There were 101 cases in non-BCG group and 91 cases in BCG group. The number of cases in the CUETO risk classification in the non-BCG group / BCG group was 0 _ 4, 5 _ 6, 7 _ 9, 10 _ 16: 58, 26, 16, 1/30, 21, 29, 11 and the tendency of the high score in the BCG group was significant (P <0.045 Fisher test). In terms of the recurrence rate, although there was no significant difference in the recurrence rate between the two groups with 36.6% / 23.1% in the non-BCG group / BCG group (p <0.54 log rank test), the BCG group with higher scores in the CUETO risk classification, there was a tendency for the recurrence rate to be low. Moreover, among of the cases who had medicated history of therapeutic agents for dysuria, the recurrence rates between in the non-BCG group 28 cases and in the BCG group 30 cases were 57.1% / 23.3% respectively which was significantly lower in the BCG group (p <0.014). On the other hand, the recurrence rate in non-BCG group 73 cases / BCG group 61 cases in non-oral cases was 28.7% / 36.1% (p <0.38), and there was no significant difference between the two groups.
CONCLUSIONS: The CUETO risk score of both groups was higher in the BCG group; however the recurrence rate tended to be higher in the non-BCG group. Therefore we think that BCG therapy would have shown the prevention effect of recurrence rate even in our study cases. Moreover, in the cases that had medicated history of therapeutic agents for dysuria, the recurrence rate was significantly higher in the non-BCG group, however, a similar trend was not observed in the BCG group. Based on the result, though it is necessary to evaluate actual urination condition in the future, there is a possibility that earlier BCG treatment intervention would be useful for recurrence prevention for a case with a history of treatment for dysuria.
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MP43-11 CHARACTERIZATION OF THE URINARY MICROBIOME IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER TREATED WITH BACILLUS CALMETTE-GU ERIN IMMUNOTHERAPY
Randy Sweis*, Shay Golan, Nimrod Barashi, Elle Hill, Ciro Andolfi, Jeffrey Bloodworth, Ryan Werntz, Gary Steinberg, Chicago, IL INTRODUCTION AND OBJECTIVES: Bacillus CalmetteGuerin (BCG) therapy is effective at preventing recurrence in many patients with high-risk, non-muscle invasive bladder cancer (NMIBC). Despite its efficacy, a significant proportion of patients (30-50%) either fail to respond or relapse within the first five years of treatment. At present, there are no clinically available biomarkers to predict response. Recent data have identified the presence of a commensal microbial population within the urine, which may impact the anti-tumor immune response in bladder cancer. Thus, we initiated a clinical study to characterize the role of the urine microbiome in the context of BCG therapy for patients.
METHODS: At a single institution, adult patients with newly diagnosed NMIBC were consented to an institutional review boardapproved clinical protocol, in order to assess the urine microbiome. Urine samples were collected prior to transurethral resection of bladder tumor (TURBT). BCG was administered to patients with high risk urothelial carcinoma. DNA was extracted using the Qiagen DNeasy PowerSoil HTP Kit and 16S sequencing data were then generated using Illumina paired-end sequencing. Operational Taxonomic Units (OTUs) were analyzed to determine the composition of the microbiome prior to BCG therapy.
RESULTS: In this study, 31 patients were enrolled, of which 9 (29%) female and 22 (71%) were male, with a median age of 69 years . At the time of data cutoff, the median follow-up was 6 months, and 10 (32%) out of 31 patients developed recurrence. There was no difference in recurrence rates between males and females (P[0.21). Proteobacteria was the most abundant phylum detected for 18 (58%) of patients. An analysis of the OTUs, based on distance matrix computation, showed a significant difference between patients with and without recurrence (Bonferroni-corrected P[0.017). The Enterobacteriales order was significantly more abundant in patients with recurrence (P[0.0012), while Lactobacillales were more abundant in patients without recurrence (P[0.049).
CONCLUSIONS: This study demonstrates the feasibility of analyzing the urinary microbiome in patients with bladder cancer undergoing TURBT and BCG therapy. Our preliminary data indicate that patients who develop recurrence have significant differences in the abundance of specific bacterial orders at baseline compared with patients without recurrence. Validation of these findings is necessary and further studies are ongoing.
